The standardized herbal formula, PM014, ameliorated cigarette smoke-induced lung inflammation in a murine model of chronic obstructive pulmonary disease

BMC Complementary and Alternative Medicine

Research Article

Miran Kim¹  Geunhyeog Lee¹  Moochang Hong²  Minkyu Shin²  Hyunsu Bae²  Kyung-Hwa Jung²  Seung Ryel Lee²  Youngeun Kim²  Soojin Park²  Kyoung-Keun Haam²  Sungki Jung³ 

[1] Central Research Institute, Hanlim Pharm. Co. Ltd., 1007 Yoobang Dong, Yongin, Kyounggi Do, Republic of Korea;Department of Physiology, College of Korean Medicine, Kyung Hee University, #1 Hoekidong, 130-701, Dongdaemoonku, Seoul, Republic of Korea;Division of Allergy and Respiratory System, Department of Internal Medicine, College of Korean Medicine, Kyung Hee University, #1 Hoekidong, 130-701, Dongdaemoonku, Seoul, Republic of Korea;

关键词: COPD;    CS;    PM014;    Neutrophil;    IL-6;    TNF-α;    MCP-1;   

DOI  :  10.1186/1472-6882-13-219

 received in 2013-04-15, accepted in 2013-08-29,  发布年份 2013

来源: Springer

【 摘 要 】

BackgroundIn this study, we evaluated the anti-inflammatory effect of PM014 on cigarette smoke induced lung disease in the murine animal model of chronic obstructive pulmonary disease (COPD).MethodsMice were exposed to cigarette smoke (CS) for 2 weeks to induce COPD-like lung inflammation. Two hours prior to cigarette smoke exposure, the treatment group was administered PM014 via an oral injection. To investigate the effects of PM014, we assessed PM014 functions in vivo, including immune cell infiltration, cytokine profiles in bronchoalveolar lavage (BAL) fluid and histopathological changes in the lung. The efficacy of PM014 was compared with that of the recently developed anti-COPD drug, roflumilast.ResultsPM014 substantially inhibited immune cell infiltration (neutrophils, macrophages, and lymphocytes) into the airway. In addition, IL-6, TNF-α and MCP-1 were decreased in the BAL fluid of PM014-treated mice compared to cigarette smoke stimulated mice. These changes were more prominent than roflumilast treated mice. The expression of PAS-positive cells in the bronchial layer was also significantly reduced in both PM014 and roflumilast treated mice.ConclusionsThese data suggest that PM014 exerts strong therapeutic effects against CS induced, COPD-like lung inflammation. Therefore, this herbal medicine may represent a novel therapeutic agent for lung inflammation in general, as well as a specific agent for COPD treatment.

【 授权许可】

Unknown   
© Jung et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.